Loading...
Please wait, while we are loading the content...
The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
| Content Provider | Semantic Scholar |
|---|---|
| Author | Chung, Fu-Tsai Ho, Ming-Yun Fang, Yueh-Fu Hshieh, Meng-Heng Wang, Tsai-Yu Kuo, Chih-Hsi Scott Chen, Hao-Cheng Wang, Chun-Hwa Lin, Shu-Min Yu, Chih-Teng Lin, Horng-Chyuan |
| Copyright Year | 2015 |
| Abstract | OBJECTIVES Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial. METHODS Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. RESULTS The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS. CONCLUSION In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding. |
| File Format | PDF HTM / HTML |
| DOI | 10.1155/2015/948267 |
| PubMed reference number | 26609535 |
| Journal | Medline |
| Volume Number | 2015 |
| Alternate Webpage(s) | http://downloads.hindawi.com/journals/bmri/2015/948267.pdf |
| Alternate Webpage(s) | https://doi.org/10.1155/2015%2F948267 |
| Journal | BioMed research international |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |